Jake Chabon

Jake Chabon

About

Detail

Co-founder/CEO
Denver, Colorado, United States

Timeline


work
Job
school
Education
auto_stories
Publication

Résumé


Jobs verified_user 0% verified
  • Foresight Diagnostics a Natera company
    Co-founder/CEO
    Foresight Diagnostics a Natera company
    Oct 2020 - Current (5 years 9 months)
    Foresight Diagnostics is an early-stage, venture-backed molecular diagnostics company that is developing non-invasive cancer detection technologies to improve the lives of patients worldwide. Our portfolio of cell-free DNA based liquid biopsy tests are rooted in novel and proprietary methods developed at Stanford University. Our approach enables the earlier detection of smaller tumors, leading to more personalized and effective cancer treatment strategies for patients. We have deep expertise in molecular biology, bioinformatics, and Next Generation Sequencing (NGS).
  • Stanford University
    Postdoctoral Fellow
    Stanford University
    Jun 2018 - Oct 2020 (2 years 5 months)
  • Stanford University School of Medicine
    PHD Candidate
    Stanford University School of Medicine
    Sep 2013 - May 2018 (4 years 9 months)
    PhD program in Stem Cell Biology and Regenerative Medicine
  • U
    Professional Research Assistant
    University of Colorado at Denver and Health Sciences Center
    Oct 2010 - May 2013 (2 years 8 months)
  • SomaScan
    Intern
    SomaScan
    Jun 2009 - Sep 2009 (4 months)
  • University of Denver
    Research Assistant
    University of Denver
    Jan 2008 - Jun 2010 (2 years 6 months)
Education verified_user 0% verified
  • Stanford University
    Doctor of Philosophy - PhD, Stem Cell Biology and Regenerative Medicine
    Stanford University
    Jan 2013 - Dec 2018 (6 years)
  • Griffith University
    Griffith University
    Griffith University
    Jan 2008 - Dec 2009 (2 years)
    Cherrington Global Scholar- Member of Cherrington study abroad program in Australia
  • University of Denver
    BS, Molecular Biology, Pre-med. Triple Minor in Business Administration, Chemistry, & Psychology.
    University of Denver
    Jan 2006 - Dec 2010 (5 years)
    Graduated Magna Cum Laude with University Honors and departmental distinction in Biological Sciences with a cumulative GPA of 3.92.
Publications verified_user 0% verified
  • N
    Integrating genomic features for non-invasive early lung cancer detection
    Nature
    Mar 2020
  • C
    Combination approach for detecting different types of alterations in circulating tumor DNA in leiomyosarcoma
    Clinical Cancer Research
    Jun 2018
  • N
    Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
    Nature Genetics
    Nov 2017
  • C
    Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling
    Cancer Discovery
    Sep 2017
    Identifying molecular residual disease (MRD) after treatment of localized lung cancer could facilitate early intervention and personalization of adjuvant therapies. Here we apply Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) circulating tumor DNA (ctDNA) analysis to 255 samples from 40 patients treated with curative intent for stage I-III lung cancer and 54 healthy adults. In 94% of evaluable patients experiencing recurrence, ctDNA was detectable in the first post-treatment blood sample, indicating reliable identification of MRD. Post-treatment ctDNA detection preceded radiographic progression in 72% of patients by a median of 5.2 months and 53% of patients harbored ctDNA mutation profiles associated with favorable responses t
  • S
    Distinct biological subtypes and patterns of genome evolution in lymphoma patients revealed by circulating tumor DNA
    Science Translational Medicine
    Nov 2016
  • N
    Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
    Nature Communications
  • N
    Integrated digital error suppression for improved detection of circulating tumor DNA
    Nature Biotechnology
  • A
    Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib
    ASCO Annual Meeting
This is a community-created genome.